BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients

We evaluated the proportion of <i>BRCA 1</i>/<i>2</i> germline mutations in Korean patients with sporadic pancreatic ductal adenocarcinoma (PDAC) and its effect on the chemotherapeutic response of FOLFIRINOX. This retrospective study included patients who were treated at two...

Full description

Bibliographic Details
Main Authors: Ji Hoon Park, Jung Hyun Jo, Sung Ill Jang, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Si Young Song, Hee Seung Lee, Jae Hee Cho
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
breast cancer gene
<i>BRCA</i>
FOLFIRINOX
pancreatic ductal adenocarcinoma
Online Access:https://www.mdpi.com/2072-6694/14/1/236

Internet

https://www.mdpi.com/2072-6694/14/1/236

Similar Items